4 open chemical decisions
Lys position
v40.22 (Lys11) vs v40.9 (HomoLys11) head-to-head; v40.24 / v40.25 extra reach reads
Chain length
C16 over-covered. v40.4 reads C18:1. C20 + saturated C18 are KAN gap-fills.
Truncation
Covered on both Nle11 (v40.2 / v40.3) and HomoLys11 (v40.10 / v40.11) scaffolds.
no linked tickets
IND stages at a glance
| Stage | Open | Overdue | Done | Next due |
|---|---|---|---|---|
| Lead optimization | 12 | 0 | 0 | 2026-07-06 |
| Stability + degradation | 2 | 0 | 0 | 2026-08-14 |
| PK (methods · studies · scaling/HED · PK-PD) | 23 | 3 | 0 | 2026-06-26 |
| Safety + immunogenicity | 4 | 0 | 0 | 2026-07-21 |
| GLP / CMC outsourcing | 8 | 0 | 0 | 2026-09-08 |
| Regulatory (AU CTN) | 3 | 0 | 0 | 2026-09-15 |
Active studies (preclin.study, last 30 days)
STU-olden-dl-dmuo-st0067 · executing
NPSv40.9 1000ug vs. NPSv40.9 500ug vs. NPSv40.9 200ug vs. NPSv40.9 100ug vs. Placebo, subq, 100ul, 0.9% saline, n = 15
owner: — · updated 2026-07-01 17:31:00.823475+00:00
STU-olden-np-ghb8-st0030 · executing
AMENv1 (500ug) vs. NPS x OXN x aMCH Co-dosed at equimolar vs. NPS (equimolar) vs. OXN (equimolar) vs. aMCH (equimolar) vs. Placebo, subQ, all in 100mM NaHCO3, n = 20
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-hr-zaqi-st0068 · executing
NPSv16.1 vs NPSv16.3 vs Placebo
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-hr-ddeu-st0099 · executing
NPSv16.3 vs. NPSv16.4 vs. NPSv18.37 vs. NPSv18.43 vs. NPSv18.47 vs. NPSv18.48 vs. NPSv34.29 vs. Placebo, 100ug, IN, 0.5% TMC, n = 20, ns.
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-np-90eg-st0012 · executing
NPSv17.1 vs. NPSv17.2 vs. NPSv17.3 vs. NPSv17.4 vs. NPSv2 vs. Placebo, IN (0.25% TMC), 50ug, n=20
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-np-xnje-st0007 · executing
NPSv16.10 vs. NPSv16.6 vs. NPSv16.7 vs. NPSv2
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-hr-3wjh-st0039 · executing
V1 in House NPS4.2 vs Placebo
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-np-meho-st0043 · executing
NPSv9.36 1mg vs. NPSv9.16 1mg vs. NPSv5.2 1mg vs. NPSv3.1 1mg vs. Placebo, subQ, 100uL saline
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-np-4qgd-st0002 · executing
NPSv9.36 vs NPSv9.16
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-hr-tn5g-st0065 · executing
NPSv9.7 vs NPSv9.16 vs Placebo
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-hr-zd8h-st0055 · executing
NPSv9.7 vs NPSv9.5 vs NPSv1
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-hr-pqor-st0027 · executing
NPSV v1 50nmol 5 cages
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-dl-7yav-st0023 · executing
OXNv27.4 vs. OXNv28.2 vs. NPSv40.18 vs. NPSv40.19 vs. OXNv16.22 vs. Placebo, IN, 0.25% TMC, n = 20
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-hr-oh5f-st0046 · executing
proNPS
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-hr-9rtv-st0050 · executing
Pro-NPS Experiments (NPSv1-proKKv1 vs - NPSv1-proNTv1 vs NPS)
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-np-ixsq-st0022 · executing
proNPSv1K8 (20ug, 100ug) vs. proNPSv2KK (20ug, 100ug) vs. proNPSv2NT (20ug, 100ug) vs. Placebo, 0.25% TMC, IN, n = 20
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-np-z563-st0019 · executing
proNPSv2KK (100ug) vs proNPSv2KK (500ug) vs proNPSv2NT (100ug) vs MOXv1 (100ug) vs MOXv1 (500ug) vs Caff (100ug) vs Plac (saline), IN, n = 20, 0.25% TMC
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-hr-tojy-st0062 · executing
Subq - (OXA vs NPSv5.2 vs Caffeine)
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-hr-bdwq-st0042 · executing
TAK 861 vs TAK 861+NPS v5.2
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-np-lsdo-st0047 · executing
500ug NPSv2-proNTv1 vs. 500ug NPSv2-proKKv1 vs. 500ug NPSv1-proK8v1 vs. 500ug NPSv1-proNTv1 vs. Placebo, n = 25
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-hr-gtsn-st0087 · executing
500ug NPSv2-proNTv1 vs. 500ug NPSv2-proKKv1 vs. 500ug NPSv1-proK8v1 vs. 500ug NPSv1-proNTv1 vs. Placebo, n = 25
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-dl-arpa-st0046 · executing
EEG NPSv40.10 100ug vs. Placebo, IN, Olden actigraphy, n = 5
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-dl-cxt2-st0058 · executing
EEG NPSv40.9 100ug vs. Placebo, IN, Olden actigraphy, n = 4
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-hr-vi2s-st0107 · executing
NPS17.5 IN 50ug vs. NPS17.5 IN 100ug vs. NPS17.5 SC 250ug vs. NPS17.5 SC 500ug vs. Veh IN vs. Veh SC, n = 5
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-hr-wld9-st0061 · executing
OXNv2 + NPSv5.2 + AZD1979 + GLP3970
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-hr-zzsy-st0063 · executing
NPSv10.13 vs NPSv10.15 vs NPSv10.1 vs NPSv10.6 vs NPSv10.14 vs Placebo (0.9% Saline)
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-nd-ucip-st0003 · executing
NPSv14 vs NPSv5.2 vs Placebo
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-nd-rrpy-st0004 · executing
NPSv14 vs NPSv5.2 vs Placebo - New Cages
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-np-t5of-st0008 · executing
NPSv16.11 (high vs. low) vs. NPSv2
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-np-ut9j-st0026 · executing
NPSv17.3 (100ug) vs. NPSv17.3 (50ug) vs. NPSv17.3 (10ug) vs. NPSv17.3 (1ug) vs. Placebo, IN, 0.25% TMC, n = 20
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-np-eqk3-st0013 · executing
NPSv18.2 (IN 0.25% TMC) vs. NPSv18.2 (subcutaneous) vs. Placebo, 100ug, n=20
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-np-pkne-st0011 · executing
NPSv18.2 vs. NPSv18.4 vs. NPSv18.6 vs. NPSv18.9 vs. NPSv2 vs. Placebo, IN (0.25% TMC), 50ug, n=25
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-hr-f4vg-st0095 · executing
NPSv18.43 100ug vs. NPSv18.47 100ug vs. NPSv18.48 100ug vs. Placebo, IN, 0.25% TMC, n = 20
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-hr-oz8t-st0049 · executing
NPSv1-proNTv1 Dose finding
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-hr-vbqo-st0101 · executing
NPSv1 vs. NPSv2 vs. NPSv3 vs. NPSv4 vs. Placebo, 100ug IN, 0.25% TMC, n = 20
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-hr-vkmq-st0074 · executing
NPSv20.1 vs NPSv20.2 vs Placebo
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-hr-de9m-st0034 · executing
NPS v2 TMC vs non TMC (Anesthesia)
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-hr-yc4g-st0040 · executing
NPS v2 vs NPS v5.2 (100ug) vs placebo
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-dl-p7x1-st0045 · executing
NPSv37.4 100ug 0.25% TMC vs. NPSv37.4 100ug 0.5% TMC vs. NPSv37.4 100ug 2.5% cyclodextrin vs. NPSv37.4 100ug 5% cyclodextrin vs. Vehicle 0.25% TMC vs. Vehicle 5% cyclodextrin, IN, 10uL, n = 20
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-hr-drt1-st0035 · executing
NPSv2 vs v3 A/TMC
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-hr-mxzv-st0094 · executing
NPSv33.4 100ug vs. NPSv33.6 100ug vs. NPSv34.6 100ug vs. NPSv34.15 100ug vs. NPSv34.25 100ug vs. NPSv34.33 100ug vs. Placebo, IN, 0.25% TMC, n = 20
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-hr-l9ns-st0075 · executing
NPsv34.1 (100ug) vs NPsv34.3 (100ug) vs NPsv34.8 (100ug) NPsv34.8 (50ug) vs NPSv17.4 (100ug) vs Placebo
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-hr-zw69-st0091 · executing
NPSv34.31 vs. NPSv34.29 vs. NPSv34.28 vs. NPSv34.26 vs. NPSv34.13 vs. NPSv34.7 vs. NPSv17.6 vs. Placebo, subQ, 1mg, 100mM NaHCO3, n = 15
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-np-7eip-st0029 · executing
NPSv34.6 (40ug) vs. NPSv34.7 (40ug) vs. NPSv34.8 (40ug) vs. NPSv34.9 (40ug) vs. Placebo (0.25% TMC), IN, n = 20
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-hr-byln-st0093 · executing
NPSv34.7 100ug vs. NPSv34.26 100ug vs. NPSv34.29 100ug vs. MOXv2.1 200ug vs. OXB 135ug vs. Placebo, IN, 0.25% TMC, n = 20
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-dl-w3um-st0043 · executing
NPSv40.19 25ug vs. NPSv40.19 50ug vs. NPSv40.19 100ug vs. NPSv40.19 200ug vs. Placebo, IN, 0.25% TMC, 10uL, n = 15
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-dl-bnkz-st0003 · executing
NPSv40.2 100ug vs. NPSv40.17 100ug vs. NPSv40.3 100ug vs. NPSv40.5 100ug vs. Placebo, IN, 100ug, 0.25% TMC, 5% HP-beta-cyclodextrin, n = 20
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-dl-wd2o-st0042 · executing
NPSv40.7 50ug 5mgmL vs. NPSv40.7 100ug 10mgmL vs. NPSv40.7 200ug 20mgmL vs. NPSv40.7 800ug 80mgmL vs. Placebo, IN, 10uL, n = 15
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-dl-qmlo-st0075 · executing
NPSv40.9 1000ug vs. NPSv40.9 500ug vs. NPSv41.7 1000ug vs. NPSv41.7 500ug vs. Placebo, subq, n = 15
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-dl-nbtc-st0044 · executing
NPSv40.9 25ug vs. NPSv40.9 50ug vs. NPSv40.9 100ug vs. NPSv40.9 200ug vs. Placebo, IN, 0.25% TMC, 10uL, n = 15
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-if-gf6g-st0018 · executing
OXNv3.1 / NPSv2 / NPSv2 + OXNv3.1
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-dl-hga4-st0078 · executing
NPSv41.18 500ug vs. NPSv41.13 500ug vs. NPSv40.9 500ug vs. Placebo, SQ, 0.9% saline, n = 15
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-dl-fswz-st0077 · executing
NPSv41.21 500ug vs. NPSv41.12 500ug vs. NPSv41.8 500ug vs. Placebo, 0.9% saline, subQ, n = 15
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-dl-lr5i-st0076 · executing
NPSv41.8 500ug vs. NPSv41.20 500ug vs. Placebo, 0.9% saline, SQ, n = 15
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-dl-ixox-st0031 · executing
NPSv50 vs. Placebo, n = 20
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-np-vbmo-st0032 · executing
NPSv5.2 (500ug) vs NPSv9.16 (500ug) vs NPSv9.36 (500ug) vs Caffeine (500ug) vs OXNv20.2 (500ug vs OXNv22.14 (500ug) vs. Placebo, subQ, NaHCO3, 100uL
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-np-mzap-st0018 · executing
NPSv5.2 dose finding (1ug/10ug/50ug/100ug) vs. NPSv34.3 (50ug) vs. Placebo, IN (0.25% TMC), n = 25
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-hr-pxbu-st0041 · executing
NPSv5.2+OXN (combined, IN) 3.1 vs TAK 861 (oral gavage) vs Placebo (oral gavage)(100ug/mouse [all drugs])
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-hr-zq1d-st0070 · executing
NPSv5.2 subq dose-finding (50ug/100ug/500ug)
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-hr-vre1-st0069 · executing
NPSv5.2 vs TAK861 vs BMS_peak2 vs SK124
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-hr-kn1w-st0060 · executing
NPSv5.3 vs Placebo -- multi-day repeated dosing
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-hr-svxg-st0059 · executing
NPSv5.3 vs. Placebo vs. NPSv5.2 vs. RTI118
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-hr-wlyq-st0057 · executing
NPSv5.3 vs SuperOXBv1 vs OXNv2
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-hr-vpv4-st0064 · executing
NPSv9.15 vs NPSv9.36 vs Placebo
owner: — · updated 2026-07-01 17:16:07.577204+00:00
Lead-lock same-plate IP1 for NPSR1 107I and 107N coverage
Determine whether the apparent 107I lead candidates retain potent full agonism on both hNPSR1 107I and 107N under matched-plate conditions, vs the prior split-plate readouts.
owner: iris · updated 2026-06-30 23:23:21.099559+00:00
Accelerated LC-MS stability triage for NPS lead-lock pair
Identify rapid parent loss or route-relevant degradation liabilities in the top NPS lead-lock candidates before the 2026-07-06 decision.
owner: iris · updated 2026-06-30 02:53:17.085537+00:00
Human albumin functional-shift screen for lipidated NPS leaders
Test whether top lipidated NPS candidates preserve functional NPSR1 agonism in human albumin conditions relevant to human half-life translation.
owner: iris · updated 2026-06-30 02:23:56.962000+00:00
Same-plate IP1 and beta-arrestin separation screen for v40 leaders
Test whether the top v40 IP1 leaders retain active Gq/IP1 signaling while avoiding strong beta-arrestin potency or high beta-arrestin Emax.
owner: iris · updated 2026-06-30 23:03:08.797599+00:00
Same-plate 107I/107N IP1 bridge for NPSv40.24 lead inclusion
Determine whether NPSv40.24 reproducibly matches or exceeds NPSv40.22 and NPSv40.9 on both hNPSR1 107I and 107N IP1 potency and Emax.
owner: iris · updated 2026-06-30 23:02:57.825929+00:00
STU-olden-hr-hwhc-st0023 · complete
NPS v2 10nmol/25nmol/50nmol/Caffeine
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-hr-tvna-st0020 · complete
NPS v2 100nmol/10nmol/1nmol/Placebo
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-hr-ibpx-st0028 · complete
NPSv 1 50/100/500nmol
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-hr-crit-st0012 · complete
[100x Underdosed] OXN v2 vs NPS V1 vs NPS V1+OXN V2
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-hr-p3hh-st0007 · complete
[100x Underdosed] NPS 2 OXN 2 OXN 3
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-hr-odrq-st0025 · complete
NPS v2 50nmol night trial
owner: — · updated 2026-07-01 17:16:07.577204+00:00
STU-olden-hr-x16t-st0017 · complete
NPS v1 25/50/100NMOL vs Placebo
owner: — · updated 2026-07-01 17:16:07.577204+00:00
Overdue across all stages (6)
| Key | Status | Due | Assignee | Vendor | CRO progress | Summary |
|---|---|---|---|---|---|---|
| KAN-20 | Idea | 2026-06-22 | Moaraj Hasan | no vendor | pick vendor (-9d to due) | SPPS synthesis - NPS 40.9 |
| KAN-24 | Idea | 2026-06-26 | Moaraj Hasan | no vendor | pick vendor (-5d to due) | PK study design + AEC (Animal Ethics Committee) protocol (mouse single-dose IV/SC) |
| KAN-21 | Idea | 2026-06-26 | Moaraj Hasan | no vendor | pick vendor (-5d to due) | RP-HPLC purification + lyophilization (NXN + NPS) |
| KAN-16 | Idea | 2026-06-26 | Moaraj Hasan | no vendor | pick vendor (-5d to due) | Peptide Synthesis & Purification |
| KAN-29 | Idea | 2026-06-30 | Moaraj Hasan | no vendor | pick vendor (-1d to due) | Reference standards, IS qualification + stock/working solutions |
| KAN-25 | Idea | 2026-06-30 | Moaraj Hasan | no vendor | pick vendor (-1d to due) | Dose formulation, dose verification, and vehicle bridging |
Compound × complete-assay coverage
"Complete" assay set: 107I IP1 · 107N IP1 · 107I FLIPR · 107N FLIPR · bArr · cAMP — same-plate, same-producer-batch.
Cells show best EC50 in nM and run count. Empty cells (—) are missing reads.
| Compound | Qty | Synth | In-vitro (cell assays) | In-vivo + stability | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IP1 (107I) | IP1 (107N) | FLIPR (107I) | FLIPR (107N) | bArr (107N) | cAMP (107N) | SC actigraphy | EEG | PK plasma | PK CSF/brain | Stability (LC-MS) | |||
NPSv40.9ANCHOR · Lead candidate — HomoLys11, 1-20, -NH2 — in all three head-to-heads SF(Nω-methyl-Arg)N(Sar)VGTG(N-Me-Nle)(HomoLys)-K[(γ-E)-(C16 Pal)]-TSFQRAKS-NH2 | not tracked | queued for SPPS | 0.00 nM · n=1 | 0.03 nM · n=2 | 0.62 nM · n=1 | 0.17 nM · n=2 | 1.47 nM · n=3 | 0.12 nM · n=2 | 0-6h: -33% sleep (NPSv41.18 500ug) 0-24h: -28% sleep (NPSv41.18 500ug) DL-HGA4-st0078 · 12 Olden runs · latest 2026-06-29 | post-lock | post-lock | post-lock | planned |
NPSv40.22Lys position · Lys11 SF(Nomega-methyl-Arg)N(Sar)VGTG(N-Me-Nle)K-K[(gamma-E)-(C16 Pal)]-TSFQRAKS-NH2 | — | queued for SPPS | — | 0.10 nM · n=1 | — | — | — | — | planned | post-lock | post-lock | post-lock | planned |
NPSv40.24Lys position · HomoHomoLys11 (secondary — extra reach) SF(Nomega-methyl-Arg)N(Sar)VGTG(N-Me-Nle)(HomoHomoLys)-K[(gamma-E)-(C16 Pal)]-TS… | not tracked | queued for SPPS | — | — | — | — | 1.85 nM · n=1 | — | planned | post-lock | post-lock | post-lock | planned |
NPSv40.25Lys position · Ornithine11 (secondary) SF(Nomega-methyl-Arg)N(Sar)VGTG(N-Me-Nle)(Orn)-K[(gamma-E)-(C16 Pal)]-TSFQRAKS-N… | not tracked | through HPLC | — | — | — | — | 2.75 nM · n=1 | — | planned | post-lock | post-lock | post-lock | planned |
NPSv40.10Truncation · 1-13 (hypothesis: default 1-20 wins; verify) SF(Nω-methyl-Arg)N(Sar)VGTG(N-Me-Nle)(HomoLys)-K[(γ-E)-(C16 Pal)]-T-NH2 | not tracked | queued for SPPS | — | 0.24 nM · n=1 | — | — | — | — | 0-6h: +22% sleep (EEG NPSv40.10 100ug) 0-24h: +71% sleep (EEG NPSv40.10 100ug) DL-arPA-st0046 · 2 Olden runs · latest 2026-06-01 | — | — | — | — |
NPSv40.11Truncation · 1-12 (hypothesis: default 1-20 wins; verify) SF(Nω-methyl-Arg)N(Sar)VGTG(N-Me-Nle)(HomoLys)-K[(γ-E)-(C16 Pal)]-NH2 | not tracked | through HPLC | — | 0.16 nM · n=1 | — | — | — | — | planned | — | — | — | — |
NPSv41.1C-terminus · -OH variant of v40.9 — critical for in-vivo effect-life decision SF(Nomega-methyl-Arg)N(Sar)VGTG(N-Me-Nle)(HomoLys)-K[(gamma-E)-(C16 Pal)]-TSFQRA… | not tracked | through HPLC | — | — | — | — | — | — | 0-6h: -33% sleep (NPSv41.18 500ug) 0-24h: -28% sleep (NPSv41.18 500ug) DL-HGA4-st0078 · 2 Olden runs · latest 2026-06-29 | post-lock | post-lock | post-lock | — |
NPSv40.23Secondary · Nω,Nω-dimethyl-Arg3 — add to cell assays where we have it (lower priority) SF(Nomega,Nomega-dimethyl-Arg)N(Sar)VGTG(N-Me-Nle)(HomoLys)-K[(gamma-E)-(C16 Pal… | not tracked | queued for SPPS | — | 1.71 nM · n=1 | — | — | 4.99 nM · n=1 | — | — | — | — | — | — |
NPSv41.12Chain length · C20 + 1-13 truncation, Lys11 (not HomoLys), -NH2 — in-vivo data in hand SF(Nomega-methyl-Arg)N(Sar)VGTGMK-K[(gamma-E)-(C20)]-T-NH2 | not tracked | partial | — | — | — | — | 15.68 nM · n=1 | — | 0-6h: -82% sleep (NPSv41.8 500ug) 0-24h: -73% sleep (NPSv41.8 500ug) DL-fsWz-st0077 · 1 Olden runs · latest 2026-06-27 | — | — | — | — |
NPSv41.7Chain length · C20 analog of v40.9 — HomoLys11, 1-20, -NH2 — SC head-to-head vs v40.9 data in hand SF(Nomega-methyl-Arg)N(Sar)VGTG(N-Me-Nle)(HomoLys)-K[(gamma-E)-(C20)]-TSFQRAKS-N… | not tracked | queued for SPPS | — | — | — | — | — | — | 0-6h: -94% sleep (NPSv40.9 500ug) 0-24h: -77% sleep (NPSv41.7 1000ug) DL-QMLo-st0075 · 2 Olden runs · latest 2026-06-25 | — | — | — | — |
NPSv41.8Chain length · C20 + 1-13 truncation, HomoLys11, -NH2 — in-vivo data in hand SF(Nomega-methyl-Arg)N(Sar)VGTG(N-Me-Nle)(HomoLys)-K[(gamma-E)-(C20)]-T-NH2 | not tracked | queued for SPPS | — | — | — | — | — | — | 0-6h: -82% sleep (NPSv41.8 500ug) 0-24h: -73% sleep (NPSv41.8 500ug) DL-fsWz-st0077 · 2 Olden runs · latest 2026-06-27 | — | — | — | — |
Planned SC mouse studies (@Jigisha)
| Study | Arms | Status / note |
|---|---|---|
| Lys11 SC study | NPSv40.9 · NPSv40.22 · NPSv40.24 · NPSv40.25 | @Jigisha — n≥20/group, 1-page plan, verify material first |
| Truncation SC study | NPSv40.9 · NPSv40.10 · NPSv40.11 | @Jigisha — n≥20/group, 1-page plan, verify material first |
| C-terminus SC study | NPSv40.9 · NPSv41.1 | @Jigisha — critical for finalising -NH2 vs -OH on in-vivo effect-life |
Synthesis workstream (@Nico, @Hillary)
Chemistry ask (@Nico): one clean ≥95% pure in-house batch each of v40.9, v40.22, v40.24, v40.25, v41.1.
| Key | Status | Due | Assignee | Vendor | CRO progress | Summary |
|---|---|---|---|---|---|---|
| KAN-20 | Idea | 2026-06-22 | Moaraj Hasan | in-house | in-house | SPPS synthesis - NPS 40.9 |
| KAN-21 | Idea | 2026-06-26 | Moaraj Hasan | in-house | in-house | RP-HPLC purification + lyophilization (NXN + NPS) |
| KAN-16 | Idea | 2026-06-26 | Moaraj Hasan | in-house | in-house | Peptide Synthesis & Purification |
Analytical QC workstream (@Mo)
| Key | Status | Due | Assignee | Vendor | CRO progress | Summary |
|---|---|---|---|---|---|---|
| KAN-17 | Idea | 2026-07-03 | Moaraj Hasan | in-house | in-house | Analytical QC / Mass Spec ID |
| KAN-14 | Idea | 2026-07-03 | Moaraj Hasan | in-house | in-house | Intact mass + full sequence confirmation MS/MS |
In-vitro potency workstream (@Stephen)
| Key | Status | Due | Assignee | Vendor | CRO progress | Summary |
|---|---|---|---|---|---|---|
| KAN-23 | Idea | 2026-07-17 | Moaraj Hasan | in-house | in-house | NPSR1 IP1 EC50 assay — NPS 40.9 |
| KAN-18 | Idea | 2026-07-17 | Moaraj Hasan | in-house | in-house | In-vitro Potency (OX2 IP1 / EC50) |
Mechanism + efficacy workstream (in-vitro target engagement, selectivity panel)
| Key | Status | Due | Assignee | Vendor | CRO progress | Summary |
|---|---|---|---|---|---|---|
| KAN-40 | Idea | 2026-07-15 | Moaraj Hasan | in-house | in-house | In-vitro target engagement + selectivity panel |
| KAN-41 | Idea | 2026-08-05 | Moaraj Hasan | in-house | in-house | In-vivo efficacy / target-engagement model (mouse) |
| KAN-42 | Idea | 2026-08-31 | Moaraj Hasan | in-house | in-house | Mechanism-of-action omics readout + brain exposure |
| KAN-6 | Idea | 2026-08-31 | Moaraj Hasan | in-house | in-house | Efficacy & Mechanism (cells, mouse, omics) |
Filed Iris gap-fills (review needed)
Some of these are now redundant with the 2026-06-30 state-of-the-union — see notes.
| KAN | Axis | Status / note |
|---|---|---|
| KAN-90 | Chain length | C20 lipid analog — realized as NPSv41.7 (HomoLys11) and NPSv41.8/v41.12 (truncated); in-vivo data confirmed, compounds promoted to LEAD_OPT_TABLE |
| KAN-91 | C-terminus | Free-acid (-OH) analog — already in flight as NPSv41.1; close as duplicate |
| KAN-92 | Chain length | Saturated C18 analog — DEFER (future-NPS lever) |
| KAN-93 | CMC | CMC + accelerated-degradation — re-scope as external-contractor work (Helena owns) |
Active engagements (3)
Populated from preclin.cro_capability — writes flow from forwarded CRO emails + Slack
@iris cro.| Vendor | Workstream | Status | Owner | CRO progress | Last engagement | Notes |
|---|---|---|---|---|---|---|
| Charles River Laboratories | glp_tox_rodent | no contract | melissa | no_contract | 2026-06-30 📧 | CRL BD contact Hank Arrington reached out to initiate CDA or MSA. Moaraj confirm |
| iHisto Inc. | histology | PO | melissa | PO live · Safety tissues shipped to iHisto Inc. (Salem, MA) | 2026-06-30 📧 | Safety tissues shipped to iHisto Inc. (Salem, MA) via UPS Next Day Air Early on |
| Charles River Laboratories | safety_pharm_ich_s7a | no contract | melissa | no_contract | 2026-06-30 📧 | CRL engaged to scope full nonclinical package including safety pharmacology as p |
Open gaps (17) — KAN tickets with no contracted vendor
| KAN | Due | Assignee | Summary |
|---|---|---|---|
| KAN-40 | 2026-07-15 | Moaraj Hasan | In-vitro target engagement + selectivity panel |
| KAN-43 | 2026-07-21 | Moaraj Hasan | In-vitro safety pharmacology (hERG, cardiovascular liability) |
| KAN-41 | 2026-08-05 | Moaraj Hasan | In-vivo efficacy / target-engagement model (mouse) |
| KAN-44 | 2026-08-10 | Moaraj Hasan | Immunogenicity / ADA assay strategy + in-silico risk |
| KAN-45 | 2026-08-31 | Moaraj Hasan | GLP tox study design + DART deferral justification |
| KAN-42 | 2026-08-31 | Moaraj Hasan | Mechanism-of-action omics readout + brain exposure |
| KAN-7 | 2026-08-31 | Moaraj Hasan | Safety & Immunogenicity (DART defer, ADA) |
| KAN-6 | 2026-08-31 | Moaraj Hasan | Efficacy & Mechanism (cells, mouse, omics) |
| KAN-71 | 2026-09-08 | Moaraj Hasan | GMP clinical batch manufacture (API) + batch record + CoA |
| KAN-75 | 2026-09-15 | Moaraj Hasan | Clinical protocol + synopsis (FIH SAD) |
| KAN-69 | 2026-09-15 | Moaraj Hasan | Genotoxicity battery (Ames + in vitro micronucleus) |
| KAN-74 | 2026-09-22 | Moaraj Hasan | Author Investigator's Brochure (IB) |
| KAN-72 | 2026-09-22 | Moaraj Hasan | Drug product CMC: sterile injectable formulation, fill-finish, container-closure |
| KAN-68 | 2026-09-22 | Moaraj Hasan | GLP repeat-dose toxicology study (non-rodent) - execution + report |
| KAN-73 | 2026-09-29 | Moaraj Hasan | ICH Q1A stability program on clinical API + DP lots |
| KAN-9 | 2026-09-30 | Moaraj Hasan | AU CTN Regulatory Package & Submission |
| KAN-8 | 2026-09-30 | Moaraj Hasan | GLP Outsourcing & CMC (engage on clinical lead) |
Stability + degradation
CRO progress (Drive): 📁 Manufacturing📁 Formulation
| Key | Status | Due | Assignee | Vendor | CRO progress | Summary |
|---|---|---|---|---|---|---|
| KAN-15 | Idea | 2026-08-14 | Moaraj Hasan | no vendor | pick vendor (44d to due) | Forced degradation study + impurity criteria |
| KAN-2 | Idea | 2026-08-14 | Moaraj Hasan | no vendor | pick vendor (44d to due) | Degradation & Stability (HF-X Orbitrap) |
PK (methods · studies · scaling/HED · PK-PD)
CRO progress (Drive): 📁 Preclinical development
| Key | Status | Due | Assignee | Vendor | CRO progress | Summary |
|---|---|---|---|---|---|---|
| KAN-24 | Idea | 2026-06-26 | Moaraj Hasan | no vendor | pick vendor (-5d to due) | PK study design + AEC (Animal Ethics Committee) protocol (mouse single-dose IV/SC) |
| KAN-29 | Idea | 2026-06-30 | Moaraj Hasan | no vendor | pick vendor (-1d to due) | Reference standards, IS qualification + stock/working solutions |
| KAN-25 | Idea | 2026-06-30 | Moaraj Hasan | no vendor | pick vendor (-1d to due) | Dose formulation, dose verification, and vehicle bridging |
| KAN-30 | Idea | 2026-07-08 | Moaraj Hasan | no vendor | pick vendor (7d to due) | Calibration curve + selectivity/specificity (ICH M10) |
| KAN-11 | Idea | 2026-07-10 | Moaraj Hasan | no vendor | pick vendor (9d to due) | 6495D MRM method dev - NPS 40.9 |
| KAN-26 | Idea | 2026-07-10 | Moaraj Hasan | no vendor | pick vendor (9d to due) | In-life dosing + serial plasma collection (0-24 h timecourse) |
| KAN-31 | Idea | 2026-07-18 | Moaraj Hasan | no vendor | pick vendor (17d to due) | Accuracy + precision validation runs (within/between-run) |
| KAN-27 | Idea | 2026-07-18 | Moaraj Hasan | no vendor | pick vendor (17d to due) | Bioanalysis of PK samples on validated 6495D method |
| KAN-12 | Idea | 2026-07-20 | Moaraj Hasan | no vendor | pick vendor (19d to due) | Plasma protein binding + blood:plasma partitioning |
| KAN-32 | Idea | 2026-07-22 | Moaraj Hasan | no vendor | pick vendor (21d to due) | Matrix effect, recovery, dilution integrity, carryover |
| KAN-35 | Idea | 2026-07-28 | Moaraj Hasan | no vendor | pick vendor (27d to due) | Cross-species in-vitro scaling inputs (clearance, binding, stability) |
| KAN-28 | Idea | 2026-07-31 | Moaraj Hasan | no vendor | pick vendor (30d to due) | Non-compartmental PK analysis + IV/SC parameter report |
| KAN-1 | Idea | 2026-07-31 | Moaraj Hasan | no vendor | pick vendor (30d to due) | In-vivo PK: mouse single-dose IV/SC (NXN 20.16 + NPS 40.9) |
| KAN-13 | Idea | 2026-08-07 | Moaraj Hasan | no vendor | pick vendor (37d to due) | In-vivo PK study report + data package of record (IV/SC) |
| KAN-33 | Idea | 2026-08-08 | Moaraj Hasan | no vendor | pick vendor (38d to due) | Stability validation (stock, bench, freeze-thaw, long-term, autosampler) |
| KAN-36 | Idea | 2026-08-10 | Moaraj Hasan | no vendor | pick vendor (40d to due) | Allometric scaling model (CL, Vss) + human PK prediction |
| KAN-38 | Idea | 2026-08-10 | Moaraj Hasan | no vendor | pick vendor (40d to due) | PK/PD biomarker + exposure-response model build |
| KAN-37 | Idea | 2026-08-21 | Moaraj Hasan | no vendor | pick vendor (51d to due) | Human starting dose: MABEL + NOAEL/BSA HED + safety factor |
| KAN-4 | Idea | 2026-08-21 | Moaraj Hasan | no vendor | pick vendor (51d to due) | Allometric Scaling & Human Starting Dose |
| KAN-34 | Idea | 2026-08-28 | Moaraj Hasan | no vendor | pick vendor (58d to due) | ICH M10 bioanalytical validation report sign-off |
| KAN-3 | Idea | 2026-08-28 | Moaraj Hasan | no vendor | pick vendor (58d to due) | Bioanalytical Method & ICH M10 Validation (6495D) |
| KAN-39 | Idea | 2026-08-28 | Moaraj Hasan | no vendor | pick vendor (58d to due) | Clinical dose-escalation scheme + projected exposure margins |
| KAN-5 | Idea | 2026-08-28 | Moaraj Hasan | no vendor | pick vendor (58d to due) | PK/PD Linkage & Dose Escalation |
Safety + immunogenicity
CRO progress (Drive): 📁 Tox Studies
| Key | Status | Due | Assignee | Vendor | CRO progress | Summary |
|---|---|---|---|---|---|---|
| KAN-43 | Idea | 2026-07-21 | Moaraj Hasan | no vendor | pick vendor (20d to due) | In-vitro safety pharmacology (hERG, cardiovascular liability) |
| KAN-44 | Idea | 2026-08-10 | Moaraj Hasan | no vendor | pick vendor (40d to due) | Immunogenicity / ADA assay strategy + in-silico risk |
| KAN-45 | Idea | 2026-08-31 | Moaraj Hasan | no vendor | pick vendor (61d to due) | GLP tox study design + DART deferral justification |
| KAN-7 | Idea | 2026-08-31 | Moaraj Hasan | no vendor | pick vendor (61d to due) | Safety & Immunogenicity (DART defer, ADA) |
GLP / CMC outsourcing
CRO progress (Drive): 📁 Manufacturing📁 Formulation
| Key | Status | Due | Assignee | Vendor | CRO progress | Summary |
|---|---|---|---|---|---|---|
| KAN-71 | Idea | 2026-09-08 | Moaraj Hasan | no vendor | pick vendor (69d to due) | GMP clinical batch manufacture (API) + batch record + CoA |
| KAN-69 | Idea | 2026-09-15 | Moaraj Hasan | no vendor | pick vendor (76d to due) | Genotoxicity battery (Ames + in vitro micronucleus) |
| KAN-67 | Idea | 2026-09-15 | Moaraj Hasan | Charles River Laboratories · no contract 📧 | no_contract | GLP repeat-dose toxicology study (rodent) - execution + report |
| KAN-72 | Idea | 2026-09-22 | Moaraj Hasan | no vendor | pick vendor (83d to due) | Drug product CMC: sterile injectable formulation, fill-finish, container-closure |
| KAN-70 | Idea | 2026-09-22 | Moaraj Hasan | Charles River Laboratories · no contract 📧 | no_contract | Safety pharmacology core battery (ICH S7A: CV, CNS, respiratory) |
| KAN-68 | Idea | 2026-09-22 | Moaraj Hasan | no vendor | pick vendor (83d to due) | GLP repeat-dose toxicology study (non-rodent) - execution + report |
| KAN-73 | Idea | 2026-09-29 | Moaraj Hasan | no vendor | pick vendor (90d to due) | ICH Q1A stability program on clinical API + DP lots |
| KAN-8 | Idea | 2026-09-30 | Moaraj Hasan | no vendor | pick vendor (91d to due) | GLP Outsourcing & CMC (engage on clinical lead) |
Regulatory (AU CTN)
CRO progress (Drive): 📁 Phase 1 trial
| Key | Status | Due | Assignee | Vendor | CRO progress | Summary |
|---|---|---|---|---|---|---|
| KAN-75 | Idea | 2026-09-15 | Moaraj Hasan | no vendor | pick vendor (76d to due) | Clinical protocol + synopsis (FIH SAD) |
| KAN-74 | In Progress | 2026-09-22 | Moaraj Hasan | no vendor | pick vendor (83d to due) | Author Investigator's Brochure (IB) |
| KAN-9 | Idea | 2026-09-30 | Moaraj Hasan | no vendor | pick vendor (91d to due) | AU CTN Regulatory Package & Submission |